Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | NUDT1 | P36639 | 3/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 2/20 | 0.38 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.38 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.38 |
| ▸ | PTPN11 | Q06124 | 7/20 | 0.37 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1733665 | 0.82 | KDM4E (0.64) | KDM4ENUDT1GRM2PIM1PIM3 | |
| SCHEMBL1734237 | 0.82 | KDM4E (0.60) | KDM4EGRM2TDP1 | |
| SCHEMBL1734243 | 0.82 | KDM4E (0.60) | KDM4EGRM2RXFP1 | |
| SCHEMBL1733748 | 0.81 | KDM4E (0.70) | KDM4EGRM2 | |
| SCHEMBL1733617 | 0.81 | KDM4E (0.69) | KDM4ESCN9AGRM2 | |
| SCHEMBL1733687 | 0.80 | KDM4E (0.75) | KDM4ESCN9A | |
| SCHEMBL1734511 | 0.79 | KDM4E (0.66) | KDM4E | |
| SCHEMBL1734416 | 0.78 | KDM4E (0.69) | KDM4ETDP1 | |
| SCHEMBL1734477 | 0.78 | KDM4E (0.65) | KDM4ERXFP1 | |
| SCHEMBL1733735 | 0.78 | KDM4E (0.76) | KDM4ESCN9AGRM2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822451-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-02 | — | — | US | claimed |
| EP-1891018-B1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMA (US) | 2011-11-16 | — | — | EP | claimed |
| WO-2011131686-A1 | A THERMALLY CONTROLLED ASSEMBLY | NAPATECH A/S (DK) | 2011-10-27 | — | — | WO | claimed |
| US-20070105833-A1 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED | 2007-05-10 | — | — | US | claimed |
| US-8822451-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-02 | — | — | US | disclosed |
| US-8822451-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-02 | — | — | US | disclosed |
| US-20070105833-A1 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED | 2007-05-10 | — | — | US | disclosed |
| US-20070105833-A1 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105833-A1 | Modulators of ATP-binding cassette transporters | ABCC4, CFTR, ABCC2 | KDM4E 3910/4885NUDT1 113/4885SCN9A 963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.